STEVENSON, Md., March 03, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces it has commenced a class action in the United States District Court for the Middle District of North Carolina on behalf of those who held the common stock of The Fresh Market, Inc. (NASDAQ:TFM) (“The Fresh Market” or the “Company”). Investors who wish to become proactively involved in the litigation have 60 days from today to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint alleges violations of Sections 14(d)(4), 14(e) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Securities and Exchange Commission (“SEC”) Rule 14d-9 against The Fresh Market’s board of directors, Pomegranate Holdings, Inc., an affiliate of Apollo Global Management, LLC (“Apollo Global”), Apollo Management VIII, L.P. (together with Apollo Global, “Apollo”), and Pomegranate Merger Sub, Inc. (“Merger Sub”), in connection with the acquisition of The Fresh Market by Apollo (“Transaction”). The complaint alleges that the Schedule 14D-9 Solicitation/Recommendation Statement filed with the SEC provided materially incomplete and false and misleading information about the Transaction, in violation of the Exchange Act. The complaint further alleges that, as a result of the false and misleading statements and material omissions, which concealed Defendants’ manipulation of the sales process for the Company, The Fresh Market shareholders received inadequate consideration for their Company shares.
If you were a shareholder of The Fresh Market and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 



